Selected article for: "ARDS patient and ECMO extracorporeal membrane oxygenation"
Author: Steinlechner, Barbara; Kargl, Gabriele; Schlömmer, Christine; Holaubek, Caroline; Scheriau, Georg; Eichinger, Sabine; Gratz, Johannes; Rössler, Bernhard
Title: Can Heparin-Coated ECMO Cannulas Induce Thrombocytopenia in COVID-19 Patients?
  • Cord-id: ape56uj4
  • Document date: 2021_6_4
    • ID: ape56uj4
    Snippet: Extracorporeal membrane oxygenation (ECMO) is often used in the management of COVID-19-related severe respiratory failure. We report the first case of a patient with COVID-19-related ARDS on ECMO support who developed symptoms of heparin-induced thrombocytopenia (HIT) in the absence of heparin therapy. A low platelet count of 61 G/L was accompanied by the presence of circulating HIT antibodies 12 days after ECMO initiation. Replacement of the ECMO system including cannulas resulted in the normal
    Document: Extracorporeal membrane oxygenation (ECMO) is often used in the management of COVID-19-related severe respiratory failure. We report the first case of a patient with COVID-19-related ARDS on ECMO support who developed symptoms of heparin-induced thrombocytopenia (HIT) in the absence of heparin therapy. A low platelet count of 61 G/L was accompanied by the presence of circulating HIT antibodies 12 days after ECMO initiation. Replacement of the ECMO system including cannulas resulted in the normalization of the platelet count. However, the clinical situation did not improve, and the patient died 9 days later. Careful consideration of anticoagulant therapy and ECMO circuit, as well as routine HIT antibody testing, may prevent a fatal course in ECMO-supported COVID-19 patients.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute ards respiratory distress syndrome and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute ards respiratory distress syndrome and low oxygenation: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute ards respiratory distress syndrome and lung protective: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • acute ards respiratory distress syndrome and lung protective ventilation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • acute ards respiratory distress syndrome and lung transplant: 1, 2, 3, 4, 5, 6, 7, 8
    • acute ards respiratory distress syndrome and lung transplantation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute ards respiratory distress syndrome and lupus anticoagulant: 1
    • acute ards respiratory distress syndrome develop and admission day: 1
    • acute ards respiratory distress syndrome develop and low molecular weight: 1, 2
    • acute ards respiratory distress syndrome develop and low molecular weight heparin: 1, 2
    • acute ards respiratory distress syndrome develop and low oxygenation: 1
    • acute ards respiratory distress syndrome develop and lung protective: 1, 2, 3
    • acute ards respiratory distress syndrome develop and lung protective ventilation: 1, 2, 3
    • acute phase and admission day: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute phase and long perform: 1
    • acute phase and low molecular weight: 1, 2, 3, 4, 5, 6, 7
    • acute phase and low molecular weight heparin: 1, 2, 3, 4, 5, 6
    • acute phase and low oxygenation: 1